Disease Control Rate (dcr) - Cancer Science

Relevant Publications

Comparison of efficacy and safety of conventional transarterial chemoembolization and drug-eluting bead transarterial chemoembolization in unresectable intrahepatic cholangiocarcinoma: A multicenter retrospective cohort study.

Issue Release: 2024

Treatment of Metastatic Biliary Cancers With Irinotecan and 5-Fluorouracil Based Chemotherapy After Platinum/Gemcitabine Progression: A Systematic Review and Meta-Analysis.

Issue Release: 2024

First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma.

Issue Release: 2024

Correlation between immune-related adverse events and efficacy of PD-(L)1 inhibitors in small cell lung cancer: a multi-center retrospective study.

Issue Release: 2024

TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.

Issue Release: 2024

Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma.

Issue Release: 2024

Cancer cachexia as a predictor of adverse outcomes in patients with non-small cell lung cancer: A meta-analysis.

Issue Release: 2024

Prognostic relevance of prognostic nutritional indices in gastric or gastro-esophageal junction cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.

Issue Release: 2024

Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment.

Issue Release: 2024

Comparative efficacy and safety of anlotinib and topotecan as second-line treatment in small cell lung cancer: a retrospective cohort study.

Issue Release: 2024

Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving Chemoimmunotherapy.

Issue Release: 2024

Evaluation of Efficacy and Safety in First-Line Treatment Methods for Extensive-Stage Small Cell Lung Cancer: A Comprehensive Comparative Study of Chemotherapy, Targeted Therapy Combined With Chemotherapy, and Immunotherapy Combined With Chemotherapy.

Issue Release: 2024

Immunotherapy combined with antiangiogenic therapy as third- or further-line therapy for stage IV non-small cell lung cancer patients with ECOG performance status 2: A retrospective study.

Issue Release: 2024

The salvage lenvatinib-based regimen provides survival benefit in patients with refractory metastatic colorectal cancer.

Issue Release: 2024

Clinical outcomes of image-guided therapies in patients with adrenocortical carcinoma: a tertiary referral center retrospective study.

Issue Release: 2024

The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification.

Issue Release: 2024

Cure can be Achieved by Conversion to Microwave Ablation following Atezolizumab-Bevacizumab Therapy in Unresectable Hepatocellular Carcinoma.

Issue Release: 2024

Comparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma.

Issue Release: 2024

Association of PD-L1 expression and clinical outcomes in ROS1 - rearranged advanced non-small cell lung cancer treated with crizotinib.

Issue Release: 2024

A novel strategy for predicting the efficacy of temozolomide treatment for metastatic pheochromocytomas/paragangliomas.

Issue Release: 2024

How Does the FDA Ensure the Safety of Cancer Drugs?

What is Viral Transmission?

How Do Healthcare Providers Implement Issue Tracking?

What is Radiation-Induced Brain Damage?

Can TGF-β be Targeted for Cancer Therapy?

Are there any challenges associated with miR-34a-based therapies?

Which Types of Cancer Are Linked to Aflatoxins?

What Cancers are Associated with MSI?

What can be done about nausea and vomiting?

What Are the Advantages of Using Fluorescence Microscopy in Cancer Research?

Disease Control Rate (dcr) - Cancer Science

Relevant Publications

Partnered Content Networks

Relevant Topics